Explore our progress to fight infections, including new awards for COVID-19


To view this email online, paste this link into your browser:
[link removed]





DONATE ([link removed])

Cystic Fibrosis Foundation
4550 Montgomery Ave, Suite 1100N
Bethesda, Maryland 20814

www.cff.org ([link removed])

As part of our comprehensive focus on fighting infections, the Cystic Fibrosis Foundation today announced more than $2.7 million ([link removed]) to support 11 laboratory studies that will explore the underlying factors that could impact COVID-19 outcomes in people with cystic fibrosis. Ultimately, insights gained from this body of research may be used to improve future treatments.

This research is just one example of the many studies funded through our Infection Research Initiative ([link removed]), a five-year commitment to invest at least $100 million to improve the detection, diagnosis, treatment, and outcomes of CF-related infections.

The Foundation already has committed more than $79 million to the initiative, and we will continue to fund any science that we believe holds real promise to address infections. In addition to $41 million in academic research awards, we are currently funding 17 industry awards focused on infection, including several targeting specific types of bacteria: 

Up to $3.3 million to Polyphor ([link removed]) to develop an inhaled version of antibiotic to treat Pseudomonas

Up to $3.75 million to Matinas BioPharma ([link removed]) to develop an oral version of antibiotic for NTM infections

Nearly $700,000 to Calibr ([link removed]) to screen for potential B. cepacia therapy

Last month, we held the first in a series of fungal research workshops, which brought together leading experts to discuss the state of the science in CF airway fungal infections, the lessons learned from clinical trials, and the possible approaches to address fungal infections. The fungal workshop series will continue through 2021 with the ultimate goal of designing a study to help address Aspergillus infections in people with CF.

We are undertaking bold steps to advance innovative solutions needed to combat the growing challenge of antibiotic resistance:

Awarding up to $5 million to Armata Pharmaceuticals ([link removed]) for the first-ever controlled clinical study of bacteriophage therapy in CF. Bacteriophage or “phage” therapy is the use of specialized viruses to treat drug-resistant infections.

Directing up to $5.6 million to Microbion Corp. ([link removed]) to develop a novel, inhaled antibiotic to treat drug-resistant infections.

Engaging with Congress ([link removed]) and other policymakers and industry leaders on solutions to promote a healthy pipeline of antibiotics.

Our CEO, Dr. Michael Boyle, discussed the state of the antibiotic pipeline at the global launch of the $1 billion AMR (Antimicrobial Research) Action Fund ([link removed]) and at the Milken Institute Future of Health Summit.

To learn more about our infection research priorities, including NTM, Aspergillus, and phage therapy, watch the webinar, “Research Overview: Infections ([link removed]),” or view our portfolio ([link removed]).





4550 Montgomery Avenue, Suite 1100N | Bethesda, MD 20814 US

This email was sent to [email protected].
To ensure that you continue receiving our emails,
please add us to your address book or safe list.

manage your preferences ([link removed])
opt out ([link removed]) using TrueRemove(r).

Got this as a forward? Sign up ([link removed]) to receive our future emails.
email powered by Emma(R)
[link removed]